| Price | $5.08 |
| Year Range | $4.23 – $7.46 |
| Market Cap | $292M |
| PE Ratio | 7.79 |
| Industry | Biotechnology |
What Is Abeona Therapeutics’s AI Stock Analysis?
Abeona Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Abeona Therapeutics’s momentum in near-real time.
Abeona Therapeutics (ABEO) has an AltIndex AI Score of 44/100, currently a Hold signal. The AI Score distills Abeona Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Abeona Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Abeona Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving ABEO’s AI Score?
Fundamentals
Revenue for the last quarter was $11M. This is an increase of 30.50% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 2,745.00%, suggesting positive year-over-year growth. Net income for the last quarter was $-20M. This represents a decrease of 18.25% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 118.55%, which may be a cause for concern. Ebitda for the last quarter was $-19M. This represents a decrease of 22.25% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 114.91%, which may be a cause for concern. The current P/E ratio is 7.79. This may be considered low, potentially indicating undervaluation and a bullish outlook. In the last couple of months, there's been a couple of company insiders selling their stock, a potentially bearish signal.
See Abeona Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $5.08. This represents a decrease of 13.16% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 10.25%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $5.10, which is lower than the previous SMA10 of $5.13. This suggests a potential downward trend in price movement. The RSI is 37.5, indicating a neutral condition.
See the full technical analysis and price prediction.
Sentiment & social
However, the sentiment is down by -6% in the last couple of weeks, a worrisome trend.
Track Abeona Therapeutics’s market sentiment.
Frequently Asked Questions: Abeona Therapeutics AI Stock Analysis
Abeona Therapeutics's AltIndex AI Score is 44/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Abeona Therapeutics a Hold (44/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Abeona Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the ABEO AI Score or sign up to read the full thesis.
